Identification of different therapeutic behavior patterns in asthma. A descriptive real-life cohort study.

05 May 2022
Clinical Research Results Abstract Introduction:Poor adherence to asthma treatment with inhaled glucocorticosteroids (ICS) leads to poor disease control. Many patients excessively rely on Short Acting Beta Agonists (SABA) as asthma rescue medication. Inappropriate use of SABA has been associated with poor disease control, need for hospital care, increased healthcare costs and mortality. Objective:To describe patterns of use of SABA and ICS in patients with asthma in a real-life primary care population. Methods:Retrospective descriptive study with prospective follow-up of the anonymous MAJORICA population cohort, for 4 years (2015-2019) to analyze behavior patterns in relation to consumption of SABA and consumption of ICS. A two-stage clusters analysis was performed to determine the greatest classifying power and clarity in interpretation.Results (table 1):11975 over 18 asthma patients on inhaled treatment and at least one ICS prescription during the study period with no COPD or other severe pulmonary disease were included. Median age 46 and 65% women. Cluster analysis showed the best classification (Cohesion and separation silhouette measure of 0.91) for four different clusters: 1 1. Patients correctly medicated, with more than 80% of prescribed maintenance medication retired from the pharmacy and no evidence for rescue medication abuse (45.6%). 1 2. Hyper-medicated patients, with more than 80% of prescribed maintenance medication retired from the pharmacy and rescue medication abuse (8.8%). 1 3. Scarcely treated patients with less than 80% of prescribed maintenance medication retired from the pharmacy and no evidence for rescue medication abuse (38.8%). 1 4. SABA abusers with less than 80% of prescribed maintenance medication retired from the pharmacy and strong evidence for rescue medication abuse (6.7%).Discussion:Certain behavior patterns can be identified in relation to the consumption of asthma medication.Declaration of interest: Astrazeneca grant. Research Idea Abstract Service Development & Evaluation Abstract Declaration of Interest References and Clinical Trial Registry Information

Resource information

Respiratory conditions
  • Asthma
Type of resource
Abstract
Conference
Malaga 2022
Author(s)
Laura López-Velasco, IBSalut